ALC vs GKOS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
ALC is the larger of the two ($35.78B market cap): the incumbent the market prices for continued execution (19.08x forward earnings, beta 0.72). GKOS is the smaller challenger ($14.00B), actually pricier on forward earnings (168.96x): more room to run, but more to prove. If you believe in growth, GKOS fits: analysts expect its revenue to rise 29% next year, against 6% for ALC. If you believe in paying less for profit, ALC fits: it trades at 19.08x forward earnings, against 168.96x for GKOS.
ALC vs GKOS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALC | GKOS | What it tells you |
|---|---|---|---|
| Market cap | $35.78B | $14.00B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 19.08 | 168.96 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.72 | 0.68 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 49% of range | 88% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.65 | 19.51 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ALC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ALC and GKOS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALC and GKOS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALC and GKOS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Alcon Inc. (ALC) do?
Alcon makes the things an ophthalmologist and an optometrist use every day. The Surgical division sells cataract equipment (the Unity VCS and CS platforms, LenSx femtosecond lasers, the ARGOS biometer, NGENUITY 3D visualization, the Constellation vitreoretinal system) plus the intraocular lenses that get implanted during those procedures, including the PanOptix and Vivity presbyopia-correcting families and the newer Clareon TruPlus monofocal and toric lenses. The Vision Care division sells contact lenses (Precision1, Precision7, Dailies Total1, Total30) and ocular health products (Systane dry eye drops, allergy and lens care lines, and the recently launched Tryptyr dry eye drug). In the third quarter of 2026 the split was roughly $1.5 billion Surgical and $1.2 billion Vision Care on $2.7 billion of total sales, so Surgical is the larger side but not overwhelmingly so. The company is headquartered in Geneva, employs about 25,000 people, traces its roots to a 1945 Fort Worth pharmacy, and has been independent since Novartis spun it off in April 2019. It passed 175 million cumulative IOL implants in March 2026.
What does Glaukos Corporation (GKOS) do?
Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. In October 2026 it added a retinal program by licensing RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The company sells through eye surgeons and clinics in the US and internationally. Growth has been accelerating: Q1 2026 net sales were roughly $150.6 million, up about 41% year over year (iDose TR contributed around $54 million), Q2 2026 net sales reached about $185.6 million, up roughly 50%, and Q3 2026 net sales reached about $211.0 million, up roughly 58%, taking trailing twelve-month revenue to about $690 million.
ALC vs GKOS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ALC drivers: Demographics that do not switch off; An unusually dense 2026 product cycle.
- GKOS drivers: iDose TR ramp; Corneal health and Epioxa.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The immediate risk is that soft cataract and premium-lens volumes are not a 2026 phenomenon, in which case growth guidance gets revised down again after multiple cuts in 2025 and 2026; implantables already shrank 2% in the September quarter. For GKOS, glaukos has only one profitable quarter behind it and trades at about 20 times trailing sales and about 169 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply.
ALC or GKOS: which should you pick?
If the story you believe is ALC's (Demographics that do not switch off), ALC is the more direct way to own it; if it is GKOS's (iDose TR ramp), GKOS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALC and GKOS guides.
ALC vs GKOS: the full fundamentals
ALC. The two P/E figures tell the whole disagreement. Trailing GAAP earnings are depressed by amortization from the Novartis separation and by the cost of running several product launches at once, which is why the stock screens at roughly 54.5 times trailing and roughly 19 times forward. Gross margin sits near 58% and cash generation is steady, so the open question is the business's growth rate after the 2026 launch wave, with management already listing 2027 headwinds. Shares have recovered from near the bottom of a ~$61.83 to ~$87.64 52-week range toward the middle, against an average analyst target around $81 from 16 analysts.
GKOS. Glaukos combines roughly 58% revenue growth with its first small quarterly profit, so it screens as a high-multiple growth medtech, not a value name, with a negative trailing P/E and a forward P/E near 169. After a roughly 149% one-year gain the stock sits just below the average analyst target of about $244. The next report, for the fourth quarter, carries consensus of about $233 million of revenue and $0.47 of EPS.
Headline figures (approximate, November 2026): ALC shows revenue (ttm) ~$11.0 billion, up ~5% year over year in Q3 2026, q3 2026 sales ~$2.74 billion (Surgical ~$1.5 billion, Vision Care ~$1.2 billion); core diluted EPS $0.91 vs $0.89 expected, margins ~58% gross, ~13% operating, ~6% net (TTM GAAP); Q3 core operating margin 21.8%, earnings per share ~$1.37 trailing GAAP; ~$3.49 core expected for 2026 and ~$3.90 for 2027; GKOS shows revenue (ttm) ~$690M, q3 2026 net sales ~$211.0M (up ~58% YoY), 2026 revenue (analyst consensus) ~$781M; 2027 ~$1.0B, gross margin ~81%.
The bottom line: ALC vs GKOS
ALC and GKOS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ALC and GKOS exposure against your real portfolio. It is not an investment adviser.
Wondering how ALC or GKOS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Alcon Inc.
Ask Walnut's AI anything about ALC and see how it fits what you own.
FAQ
What is the difference between ALC and GKOS?
+
Alcon makes the things an ophthalmologist and an optometrist use every day. Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALC or GKOS the better stock?
+
Neither is universally better. ALC is the larger incumbent; GKOS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALC or GKOS?
+
On forward P/E (as of November 2026), ALC trades at 19.08x and GKOS at 168.96x, so ALC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALC and GKOS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALC vs GKOS?
+
ALC: The immediate risk is that soft cataract and premium-lens volumes are not a 2026 phenomenon, in which case growth guidance gets revised down again after multiple cuts in 2025 and 2026; implantables already shrank 2% in the September quarter. The gap between reported and core earnings is wide (trailing GAAP EPS around $1.37 against 2026 core estimates near $3.49), so bulls and bears citing Alcon's P/E are often quoting about 55 times and about 19 times for the same stock as of November 2026. Balance-sheet debt is ~$5.3 billion against ~$1.8 billion of cash. Management has named 2027 headwinds: lapping the Unity rollout, the non-recurring ~$60 million of 2026 tariff refunds, a $15 million milestone payment, memory and resin inflation, and dilution from Neurotech. As a Swiss-domiciled company reporting in dollars, currency moves swing reported growth several points in either direction. Competition is intense on both sides of the business: Johnson & Johnson MedTech and Bausch + Lomb in surgical and IOLs, Cooper Companies and J&J in contact lenses, with international contact lens markets growing only 1% to 2%. Two attempted deals failed in quick succession (LENSAR terminated in March 2026 over FTC opposition, and STAAR Surgical shareholders rejected Alcon's $30.75 per share offer in January 2026), and the ENCELTO ramp is the next test of whether the company can add inorganic growth. GKOS: Glaukos has only one profitable quarter behind it and trades at about 20 times trailing sales and about 169 times forward earnings, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter. The shares have swung widely, from a 52-week low near $94 to a high near $255, and rose about 32% in the month to November 20, 2026, so the price now sits close to the average analyst target of about $244. The new RO-104 retinal license adds early-stage development risk.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALC or GKOS; figures are approximate and dated (as of November 2026). Verify current data before investing.